The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
OXA-48-like carbapenemases: the phantom menace
Abstract
OXA-48-type carbapenem-hydrolysing class D β-lactamases are increasingly reported in enterobacterial species. To date, six OXA-48-like variants have been identified, with OXA-48 being the most widespread. They differ by a few amino acid substitutions or deletions (one to five amino acids). The enzymes hydrolyse penicillins at a high level and carbapenems at a low level, sparing broad-spectrum cephalosporins, and are not susceptible to β-lactamase inhibitors. When combining permeability defects, OXA-48-like producers may exhibit a high level of resistance to carbapenems. OXA-163 is an exception, hydrolysing broad-spectrum cephalosporins but carbapenems at a very low level, and being susceptible to β-lactamase inhibitors. The bla(OXA-48)-type genes are always plasmid-borne and have been identified in association with insertion sequences involved in their acquisition and expression. The current spread of the bla(OXA-48) gene is mostly linked to the dissemination of a single IncL/M-type self-transferable plasmid of 62 kb that does not carry any additional resistance gene. OXA-48-type carbapenemases have been identified mainly from North African countries, the Middle East, Turkey and India, those areas constituting the most important reservoirs; however, occurrence of OXA-48 producers in European countries is now well documented, with some reported hospital outbreaks. Since many OXA-48-like producers do not exhibit resistance to broad-spectrum cephalosporins, or only decreased susceptibility to carbapenems, their recognition and detection can be challenging. Adequate screening and detection methods are therefore required to prevent and control their dissemination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Spread of Carbapenemase-producing Enterobacteriaceae
Nordmann, P., Naas, T., & Poirel, L. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110655 · Cited by 2,378
Self-citationMultiplex PCR for detection of acquired carbapenemase genes
Poirel, L., Walsh, T. R., Cuvillier, V., & Nordmann, P. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.12.002 · Cited by 1,991
Self-citationResistance Plasmid Families in Enterobacteriaceae
Carattoli, A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01707-08 · Cited by 1,229
Emergence of Oxacillinase-Mediated Resistance to Imipenem in Klebsiella pneumoniae
Poirel, L., Héritier, C., Tolün, V., & Nordmann, P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.15-22.2004 · Cited by 997
Self-citationEUCAST expert rules in antimicrobial susceptibility testing
Leclercq, R., Cantón, R., Brown, D. F. J., Giske, C. G., Heisig, P., MacGowan, A. P., Mouton, J. W., Nordmann, P., Rodloff, A. C., Rossolini, G. M., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03703.x · Cited by 683
Self-citationThe emerging NDM carbapenemases
Nordmann, P., Poirel, L., Walsh, T. R., & Livermore, D. M. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.09.005 · Cited by 663
Self-citationDiversity, Epidemiology, and Genetics of Class D β-Lactamases
Poirel, L., Naas, T., & Nordmann, P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01512-08 · Cited by 632
Self-citationIdentification and screening of carbapenemase-producing Enterobacteriaceae
Nordmann, P., Gniadkowski, M., Giske, C. G., Poirel, L., Woodford, N., & Miriagou, V. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03815.x · Cited by 408
Self-citationCastanheira, M., Deshpande, L. M., Mathai, D., Bell, J. M., Jones, R. N., & Mendes, R. E. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01497-10 · Cited by 362
Poirel, L., Decousser, J.-W., & Nordmann, P. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.2938-2945.2003 · Cited by 357
Self-citation
Cited by
Dissemination of Antimicrobial Resistance in Microbial Ecosystems through Horizontal Gene Transfer
von Wintersdorff, C. J. H., Penders, J., van Niekerk, J. M., Mills, N. D., Majumder, S., van Alphen, L. B., Savelkoul, P. H. M., & Wolffs, P. F. G. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00173 · Cited by 1,707
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
Munoz-Price, L. S., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M., Cornaglia, G., Garau, J., Gniadkowski, M., Hayden, M. K., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70190-7 · Cited by 1,627
Self-citationLogan, L. K., & Weinstein, R. A. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw282 · Cited by 1,584
β-Lactamases and β-Lactamase Inhibitors in the 21st Century
Tooke, C. L., Hinchliffe, P., Bragginton, E. C., Colenso, C. K., Hirvonen, V. H. A., Takebayashi, Y., & Spencer, J. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.002 · Cited by 1,016
The global epidemiology of carbapenemase-producing Enterobacteriaceae
van Duin, D., & Doi, Y. (2017) · Virulence · doi:10.1080/21505594.2016.1222343 · Cited by 1,004
Epidemiology of β-Lactamase-Producing Pathogens
Bush, K., & Bradford, P. A. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00047-19 · Cited by 938
Mathers, A. J., Peirano, G., & Pitout, J. D. D. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00116-14 · Cited by 872
Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance
Pitout, J. D. D., Nordmann, P., & Poirel, L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01019-15 · Cited by 852
Self-citationPast and Present Perspectives on β-Lactamases
Bush, K. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01076-18 · Cited by 832
Evans, B. A., & Amyes, S. G. B. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00117-13 · Cited by 815
Carbapenem Resistance: A Review
Codjoe, F., & Donkor, E. (2017) · Medical Sciences · doi:10.3390/medsci6010001 · Cited by 746
Lee, C.-R., Lee, J. H., Park, K. S., Kim, Y. B., Jeong, B. C., & Lee, S. H. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00895 · Cited by 739
Carbapenem resistance: overview of the problem and future perspectives
Meletis, G. (2016) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936115621709 · Cited by 725
The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide
Nordmann, P., & Poirel, L. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12719 · Cited by 679
Self-citationCarbapenemase-Producing Organisms: A Global Scourge
Bonomo, R. A., Burd, E. M., Conly, J., Limbago, B. M., Poirel, L., Segre, J. A., & Westblade, L. F. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix893 · Cited by 656
Self-citationAntibiotic resistance increases with local temperature
MacFadden, D. R., McGough, S. F., Fisman, D., Santillana, M., & Brownstein, J. S. (2018) · Nature Climate Change · doi:10.1038/s41558-018-0161-6 · Cited by 560
Interplay between β-lactamases and new β-lactamase inhibitors
Bush, K., & Bradford, P. A. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0159-8 · Cited by 531
Mechanisms of antimicrobial resistance in Gram-negative bacilli
Ruppé, É., Woerther, P.-L., & Barbier, F. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0061-0 · Cited by 490
The Global Ascendency of OXA-48-Type Carbapenemases
Pitout, J. D. D., Peirano, G., Kock, M. M., Strydom, K.-A., & Matsumura, Y. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-19 · Cited by 478
Antimicrobial pharmaceuticals in the aquatic environment - occurrence and environmental implications
Felis, E., Kalka, J., Sochacki, A., Kowalska, K., Bajkacz, S., Harnisz, M., & Korzeniewska, E. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172813 · Cited by 437
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
Morrill, H. J., Pogue, J. M., Kaye, K. S., & LaPlante, K. L. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv050 · Cited by 435
“Stormy waters ahead”: global emergence of carbapenemases
Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423
Pierce, V. M., Simner, P. J., Lonsway, D. R., Roe-Carpenter, D. E., Johnson, J. K., Brasso, W. B., Bobenchik, A. M., Lockett, Z. C., Charnot-Katsikas, A., Ferraro, M. J., et al. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00193-17 · Cited by 405
The rapid spread of carbapenem-resistant Enterobacteriaceae
Potter, R. F., D’Souza, A. W., & Dantas, G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.09.002 · Cited by 403
Infections Caused by Resistant Gram‐Negative Bacteria: Epidemiology and Management
Kaye, K. S., & Pogue, J. M. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1636 · Cited by 383
Laboratory Detection of Enterobacteriaceae That Produce Carbapenemases
Doyle, D., Peirano, G., Lascols, C., Lloyd, T., Church, D. L., & Pitout, J. D. D. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-12 · Cited by 363
The emerging threat of multidrug-resistant Gram-negative bacteria in urology
Zowawi, H. M., Harris, P. N. A., Roberts, M. J., Tambyah, P. A., Schembri, M. A., Pezzani, M. D., Williamson, D. A., & Paterson, D. L. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.199 · Cited by 361
Tackling Threats and Future Problems of Multidrug-Resistant Bacteria
Medina, E., & Pieper, D. H. (2016) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2016_492 · Cited by 356
Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections
Suay-García, B., & Pérez-Gracia, M. T. (2019) · Antibiotics · doi:10.3390/antibiotics8030122 · Cited by 344
Escherichia coli: an old friend with new tidings
Vila, J., Sáez-López, E., Johnson, J. R., Römling, U., Dobrindt, U., Cantón, R., Giske, C. G., Naas, T., Carattoli, A., Martínez-Medina, M., et al. (2016) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuw005 · Cited by 335
Ma, J., Song, X., Li, M., Yu, Z., Cheng, W., Yu, Z., Zhang, W., Zhang, Y., Shen, A., Sun, H., et al. (2023) · Microbiological Research · doi:10.1016/j.micres.2022.127249 · Cited by 308
Seiffert, S. N., Hilty, M., Perreten, V., & Endimiani, A. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2012.12.001 · Cited by 296
Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates
Tamma, P. D., & Simner, P. J. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01140-18 · Cited by 293
Potron, A., Poirel, L., Rondinaud, E., & Nordmann, P. (2013) · Eurosurveillance · doi:10.2807/1560-7917.es2013.18.31.20549 · Cited by 289
Self-citationHammoudi Halat, D., & Ayoub Moubareck, C. (2020) · Antibiotics · doi:10.3390/antibiotics9040186 · Cited by 287
New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
Drawz, S. M., Papp-Wallace, K. M., & Bonomo, R. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00826-13 · Cited by 286
Mutuku, C., Gazdag, Z., & Melegh, S. (2022) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-022-03334-0 · Cited by 280
Lan, P., Jiang, Y., Zhou, J., & Yu, Y. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.02.020 · Cited by 280
Carbapenemase-producing Enterobacteriaceae: Overview of a major public health challenge
Nordmann, P. (2014) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2013.11.007 · Cited by 279
Self-citationZurfluh, K., Hächler, H., Nüesch-Inderbinen, M., & Stephan, R. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.00054-13 · Cited by 272
Carbapenem-Resistant Enterobacteriaceae
Iovleva, A., & Doi, Y. (2017) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2017.01.005 · Cited by 263
Carbapenemase-Producing Enterobacteriaceae
Paterson, D., & Doi, Y. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0035-1544208 · Cited by 257
Satlin, M. J., Jenkins, S. G., & Walsh, T. J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu052 · Cited by 255
Highly drug-resistant Salmonella enterica serotype Kentucky ST198-X1: a microbiological study
Le Hello, S., Harrois, D., Bouchrif, B., Sontag, L., Elhani, D., Guibert, V., Zerouali, K., & Weill, F.-X. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70124-5 · Cited by 186
Ouédraogo, A.-S., Compain, F., Sanou, M., Aberkane, S., Bouzinbi, N., Hide, M., Sangaré, L., Ouédraogo-Traoré, R., Jean-Pierre, H., Vendrell, J., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00147-16 · Cited by 23
“The same genetic context was recovered in all six blaOXA-181surrounding sequences available in the GenBank database (GenBank accession numbers KP400525, AB972272, JN205800, NZ_JRKW01000020, JQ996150, and KT005457) (11, 12).”
BackgroundDuran-Bedolla, J., Téllez-Sosa, J., Bocanegra-Ibarias, P., Schilmann, A., Bravo-Romero, S., Reyna-Flores, F., Villa-Reyes, T., & Barrios-Camacho, H. (2024) · Applied and Environmental Microbiology · doi:10.1128/aem.01165-24 · Cited by 15
Multifunctionality of statins as antimicrobials
Plotkin, B. J., Borrelli, A., Erbst, M., Zheng, V., Konaklieva, M. I., Schileru, N., & Sigar, I. M. (2022) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2022.11.3.0114 · Cited by 1
Metadata
- Authors
- Poirel, L., Potron, A., & Nordmann, P.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-04-11
- Volume
- 67
- Issue
- 7
- Pages
- 1597-1606
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2141966178
- Cited by
- 924
- References
- 39
- FWCI
- 28.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.